Scientific Publications

Advancing dermatological science.

September 2024 Featured

JAMA Dermatology

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

December 2025

J Clin Aesthet Dermatol

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology

August 2025

Pediatric Dermatology

Early evidence of safety, clinical benefit, and PK of roflumilast cream 0.3% once daily in children 2–11 (psoriasis)

February 2025

Pediatric Dermatology

Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric AD age 2–5 (INTEGUMENT-PED)

January 2025

Dermatitis

Long-term safety & efficacy with roflumilast cream 0.15% (≥6y, open-label extension)

November 2024

J Invest Dermatol

Chemical, biochemical, and structural similarities/differences of dermatological cAMP PDE-IV inhibitors

October 2024

Journal of Drugs in Dermatology

Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema

August 2024

JAAD

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

March 2024

EADV 2024

Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Patients With Diverse Skin Types: Pooled Subgroup Analysis From the Phase 3 INTEGUMENT-1 and -2 Trials

March 2024

AAD 2024

Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient-Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2)

March 2024

AAD 2024

Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis

March 2024

AAD 2024

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients 2 to 5 Years of Age with Mild to Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download